Literature DB >> 7869314

Antibodies to Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis in ankylosing spondylitis: effect of sulfasalazine treatment.

M Nissilä1, R Lahesmaa, M Leirisalo-Repo, K Lehtinen, P Toivanen, K Granfors.   

Abstract

OBJECTIVE: To make a longitudinal study of antibodies to Klebsiella pneumoniae in patients with ankylosing spondylitis (AS) and to assess treatment effects. As a comparison we measured antibodies of 2 other gut associated bacteria, Escherichia coli and Proteus mirabilis.
METHODS: In a double blind study in 84 Finnish outpatients with AS before and after 26 weeks' treatment with sulfasalazine or placebo we measured serum antibodies to Klebsiella pneumoniae, E. coli and Proteus mirabilis with ELISA: Serum samples of 100 healthy blood donors served as controls.
RESULTS: The levels of IgA class antibodies to all 3 bacteria were statistically significantly higher in the sera of the patients compared to the controls. During sulfasalazine treatment significant decreases were observed in concentrations of the IgA class antibodies to Klebsiella and E. coli whereas only a slight decrease was observed in the concentrations of IgA antibodies to Proteus mirabilis. There were no correlations between the clinical and laboratory results observed with sulfasalazine and decrease in concentrations of IgA class antibodies.
CONCLUSION: Our results agree with the role of gut associated lymphoid tissue in the pathogenesis of AS, but do not totally exclude Klebsiella pneumoniae as a specific agent contributing to the development of AS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7869314

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

Review 1.  HLA-B27 and bacteria.

Authors:  J Uksila; P Toivanen
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

Review 2.  Clinical, bacteriological, and serological aspects of Klebsiella infections and their spondylarthropathic sequelae.

Authors:  H Sahly; R Podschun
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

3.  Enhanced jejunal production of antibodies to Klebsiella and other Enterobacteria in patients with ankylosing spondylitis and rheumatoid arthritis.

Authors:  O Mäki-Ikola; R Hällgren; L Kanerud; N Feltelius; L Knutsson; K Granfors
Journal:  Ann Rheum Dis       Date:  1997-07       Impact factor: 19.103

4.  Infectious background of patients with a history of acute anterior uveitis.

Authors:  M Huhtinen; K Laasila; K Granfors; M Puolakkainen; I Seppälä; L Laasonen; H Repo; A Karma; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 5.  The use of a low starch diet in the treatment of patients suffering from ankylosing spondylitis.

Authors:  A Ebringer; C Wilson
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

6.  IgA1 and IgA2 subclass antibodies against Klebsiella pneumoniae in the sera of patients with peripheral and axial types of ankylosing spondylitis.

Authors:  O Mäki-Ikola; M Nissilä; K Lehtinen; M Leirisalo-Repo; K Granfors
Journal:  Ann Rheum Dis       Date:  1995-08       Impact factor: 19.103

7.  Antibody responses after documented COVID-19 disease in patients with autoimmune rheumatic disease.

Authors:  Padmanabha Shenoy; Sakir Ahmed; K C Shanoj; Veena Shenoy; Deepak Damodaran; Aparna R Menon; Bazil Alias; Divya Devakumar; A S Sageer Babu
Journal:  Clin Rheumatol       Date:  2021-06-22       Impact factor: 2.980

8.  Reactive arthritis and other musculoskeletal symptoms associated with acquisition of diarrhoeagenic Escherichia coli (DEC).

Authors:  Riitta Tuompo; Tinja Lääveri; Timo Hannu; Sari H Pakkanen; Juha Kirveskari; Marjatta Leirisalo-Repo; Anu Kantele
Journal:  Ann Rheum Dis       Date:  2020-03-16       Impact factor: 19.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.